A5047181213- Chronic Obstructive Pulmonary Disease (COPD) Research
- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Respiratory Support and Mechanisms
- Inhalation and Respiratory Drug Delivery
- Delphi Technique in Research
- Allergic Rhinitis and Sensitization
- Nursing Diagnosis and Documentation
- School Health and Nursing Education
- Pediatric health and respiratory diseases
- Chronic Disease Management Strategies
- IL-33, ST2, and ILC Pathways
- Influenza Virus Research Studies
- Family and Patient Care in Intensive Care Units
- Child and Adolescent Health
- Health Literacy and Information Accessibility
- Mobile Health and mHealth Applications
- Health, psychology, and well-being
- Respiratory viral infections research
- Themes in Literature Analysis
- Health Sciences Research and Education
- Climate Change and Health Impacts
- Pharmaceutical studies and practices
- Air Quality and Health Impacts
- Patient-Provider Communication in Healthcare
UNSW Sydney
2017-2025
The University of Sydney
2016-2025
Concord Repatriation General Hospital
2016-2025
The George Institute for Global Health
2016-2025
Woolcock Institute of Medical Research
2012-2024
George Institute for Global Health
2013-2024
Cardiff University
2024
RCSI & UCD Malaysia Campus
2024
Concord Hospital
2003-2023
American Thoracic Society
2001-2023
Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown.We conducted a randomized, double-blind trial comparing salmeterol at dose of 50 microg plus fluticasone propionate 500 twice daily (combination regimen), administered with single inhaler, placebo, alone, or alone for period 3 years. The primary outcome was death from any cause the comparison between combination regimen placebo;...
Chronic obstructive pulmonary disease (COPD) is characterized by an accelerated decline in lung function. No drug has been shown conclusively to reduce this decline.In a post hoc analysis of the Toward Revolution COPD Health (TORCH) study, we investigated effects combined salmeterol 50 microg plus fluticasone propionate 500 microg, either component alone or placebo, on rate post-bronchodilator FEV(1) patients with moderate severe COPD.A randomized, double-blind, placebo-controlled study was...
<b>Aim:</b> To study the expression of claudins in mesothelioma and metastatic pleural adenocarcinoma. <b>Methods:</b> Immunohistochemical staining 1, 2, 3, 4, 5, 7 was studied 35 malignant mesotheliomas compared with 24 cases All were also immunostained calretinin. <b>Results:</b> Claudin seen 40%, 80%, 18%, 23%, 14%, 43% mesotheliomas, respectively, while corresponding figures for adenocarcinoma 100%, 88%, 90%, 50%, 92%. Claudins significantly less positive than adenocarcinoma, no...
Inhaled corticosteroids (ICS) are important in reducing exacerbation frequency associated with chronic obstructive pulmonary disease (COPD). However, little is known about the risk of infections. In a post hoc analysis TOwards Revolution COPD Health (TORCH) study, we analysed and identified potential factors for adverse event reports pneumonia this randomised, double-blind trial comparing twice-daily inhaled salmeterol (SAL) 50 μg, fluticasone propionate (FP) 500 combination (SFC) placebo...
The efficacy of inhaled salmeterol plus fluticasone propionate (SFC) in patients with severe or very COPD is well documented. However, there are only limited data about the influence GOLD severity staging on effectiveness SFC, particularly milder disease. TORCH was a 3-year, double-blind, placebo-controlled trial 6112 moderate/severe pre-bronchodilator FEV1 < 60% predicted (mean age 65 years, 76% male, mean 44% FEV1, 43% current smokers). To understand relative SFC and its components by...
BackgroundAsthma pathophysiology and treatment responsiveness are predicted by inflammatory phenotype. However, the relationship between airway microbiology asthma phenotype is poorly understood.ObjectiveWe aimed to characterize microbiota in patients with symptomatic stable relate composition other phenotypic characteristics.MethodsThe microbial of induced sputum specimens collected from adult screened for a multicenter randomized controlled trial was determined using 16S rRNA gene...
Summary Background In asthma, the airway inflammatory phenotype influences clinical characteristics and treatment response. Although induced sputum is gold standard test for phenotyping a more accessible method needed practice. Objective To investigate whether white blood cell counts and/or their derived ratios can predict eosinophils or neutrophils in uncontrolled asthma. Methods This cross‐sectional study evaluated 164 treated but asthmatic patients with induction collection....
Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with severe eosinophilic needed to assess whether the from randomised controlled trials are applicable broader population. The Australian Mepolizumab Registry (AMR) was established an aim use, effectiveness and safety of for Australia. Patients (n=309) (median age 60 years, 58% female) commenced mepolizumab. They had poor symptom control Asthma Control Questionnaire (ACQ)-5 score 3.4), frequent exacerbations...
Rationale: The macrolide antibiotic azithromycin reduces exacerbations in adults with persistent symptomatic asthma. However, owing to the pleotropic properties of macrolides, unintended bacteriological consequences such as augmented pathogen colonization or dissemination antibiotic-resistant organisms can occur, calling into question long-term safety maintenance therapy.Objectives: To assess effects on airway microbiota, abundance, and carriage resistance genes.Methods: 16S rRNA sequencing...
To determine predictors for failed reduction of inhaled corticosteroids (ICS), in 50 subjects with well-controlled asthma (age 43.7 [18–69]; 22 males) taking a median dose 1,000 μ g ICS/d (100–3,600 g/d), ICS were halved every 8 wk. Airway hyperresponsiveness (AHR) to bronchial provocation test (BPT) histamine was measured at baseline. AHR BPT mannitol, spirometry, exhaled nitric oxide (eNO), and, 31 subjects, sputum inflammatory cells baseline and monthly intervals. Thirty-nine suffered an...
We investigated the impact of season relative to other determinants chronic obstructive pulmonary disease (COPD) exacerbation frequency in a long-term international study patients with forced expiratory volume 1 s (FEV ) <60% predicted. COPD exacerbations were defined by worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate) or hospital admission (severe). Seasonality effect was calculated as proportion experiencing an each month. Exacerbations northern and...
<h3>Background</h3> Previous studies have suggested that long-term use of β agonists to treat chronic obstructive pulmonary disease (COPD) may increase the risk cardiovascular adverse events. In this post hoc analysis, data from TOwards a Revolution in COPD Health (TORCH) study were used investigate whether long-acting β<sub>2</sub> agonist salmeterol over 3 years increased events patients with moderate severe COPD. <h3>Methods</h3> TORCH was randomised, double-blind, placebo controlled...
There is limited knowledge regarding sex differences and outcomes in patients with chronic obstructive pulmonary disease (COPD).Determine survival, causes of death, patient-centered the 3-year Toward a Revolution COPD Health (TORCH) study.A total 1,481 women 4,631 men were enrolled TORCH, trial comparing salmeterol, 50 μg, plus fluticasone propionate, 500 twice day each component individually. Causes death determined by an endpoint committee. Sex survival explored using Cox proportional...